Study finds no clear link between antibiotic timing and outcomes after stem cell transplant
A small, single-center review of fever episodes found no detectable association, but larger studies are needed.
Low evidenceHuman studyInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The study included adults who had not received intravenous antibiotics in the 24 hours before developing neutropenic fever. Researchers compared episodes in which antibiotics were given within one hour with those in which treatment took longer, and they also analyzed time to antibiotics hour by hour.
Among the 224 episodes, 17 involved clinical deterioration, defined as a new need for blood-pressure-supporting drugs for at least six hours, mechanical ventilation, or death within 90 days. The researchers found no statistically clear association between antibiotic timing and deterioration. They also found no clear association between recognized bacterial infection in the blood and 90-day mortality. The authors said multicenter research is needed.
What the study looked at
This retrospective cohort study examined 224 episodes of neutropenic fever among adults within 30 days after hematopoietic stem cell transplant at one academic center from 2018 through 2022. The analysis included only episodes in which patients had not received intravenous antibiotics during the preceding 24 hours and for which the antibiotic timing was validated. The main outcome was clinical deterioration, defined as a new vasopressor requirement lasting at least six hours, mechanical ventilation, or death within 90 days. Secondary outcomes included bloodstream infection and blood-culture results.
Key observations
The median time to antibiotics was 1.2 hours, and 86 of 224 episodes, or 38.4%, received antibiotics within one hour. Seventeen episodes, or 7.6%, met the study definition of clinical deterioration. After statistical adjustment, deterioration was not clearly associated with receiving antibiotics within one hour compared with receiving them later; the reported adjusted odds ratio was 1.18, with a 95% confidence interval from 0.37 to 3.78. An analysis treating each additional hour separately also found no clear association.
Recognized bacterial infection in the blood occurred in 59 episodes, or 26.3%, and was not clearly associated with 90-day mortality. There were 11 deaths, and 10 occurred without a preceding episode of acute deterioration. Blood cultures collected before and after antibiotics had similar rates of recognized pathogens. These findings describe associations in this study group and do not establish that antibiotic timing has no effect.
Where this may apply
The findings may be relevant to adults who are similar to those studied: patients at one center who developed neutropenic fever within 30 days of hematopoietic stem cell transplant and had not recently received intravenous antibiotics. They do not directly apply to other patient groups, including children, people with different types or timing of transplant, patients already receiving antibiotics, or people with septic shock or other infections. Because this was a single-center observational study, its results should not be interpreted as evidence that a particular antibiotic delay is appropriate or harmless.
Why it matters
Guidelines commonly recommend giving initial antibiotics within one hour for neutropenic fever, although the abstract says this recommendation was largely extrapolated from research on sepsis. This study raises uncertainty about how strongly small differences in timing are linked to outcomes specifically among antibiotic-naive adults soon after stem cell transplant. It does not overturn clinical guidelines, establish a safe delay, or show that timing is unimportant.
Limitations & evidence assessment
The study was retrospective and observational, so differences between patient episodes could have influenced both antibiotic timing and outcomes. It was conducted at a single academic center, which may limit how well the findings apply elsewhere. The sample included 224 episodes, but only 17 involved clinical deterioration and 11 involved death, making estimates imprecise; this is reflected in the wide confidence intervals. The study included only antibiotic-naive adults within 30 days of transplant and may not apply to children, later post-transplant periods, people who had recently received antibiotics, or other fever and sepsis settings. The abstract does not provide enough detail to assess all possible sources of bias or how treatment decisions were made.
Why this evidence level: This was a retrospective, single-center observational cohort of 224 fever episodes, with only 17 episodes involving clinical deterioration. It can identify associations in this group but cannot establish that antibiotic timing causes or does not cause outcomes, and the findings need confirmation at other centers.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Supportive Care in Cancer · 2026 · DOI: 10.1007/s00520-026-11141-8
This systematic review and meta-analysis examined whether ultra-low-dose computed tomography (CT) can detect pulmonary, or lung, nodules while using less radiation than standard-dose CT. Across 42 studies involving 15,792 patients, pooled sensitivity for nodule detection was 91.9%, but results varied greatly between studies. The review also found that ultra-low-dose CT used an average effective dose of 0.22 millisieverts (mSv), while detection was less reliable for some small or hazy nodules and in patients with a high body mass index.
In an online randomized experiment involving 3,519 Chilean parents, researchers tested whether adding an “ULTRAPROCESSED” warning to Chile’s existing nutrient labels changed views of potato chips. The added label improved identification of ultraprocessed products and lowered reported purchase intentions and perceived healthfulness, but the effects were smaller when products already had more nutrient warnings. The study measured stated responses, not actual purchases or health outcomes.
A systematic review and network meta-analysis examined nonhormonal prescription medicines for hot flashes and related symptoms among adult women with breast cancer or a history of breast cancer. Across 19 study or substudy records involving 2,224 participants, five medicines showed statistically greater symptom improvement than placebo, but the evidence for comparing safety between medicines was limited.
